{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma+Non-resectable&page=7",
    "query": {
      "condition": "Pancreatic Carcinoma Non-resectable",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 214,
    "total_pages": 22,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma+Non-resectable&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma+Non-resectable&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T23:00:02.906Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01373164",
      "title": "A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms",
        "Neoplasm Metastasis",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Galunisertib",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2011-06",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2018-05-16",
      "last_synced_at": "2026-11-19T23:00:02.906Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Harvey, Illinois • Seattle, Washington",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01373164"
    },
    {
      "nct_id": "NCT07756281",
      "title": "First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Pancreatic Acinar Carcinoma"
      ],
      "interventions": [
        {
          "name": "SNV1521",
          "type": "DRUG"
        },
        {
          "name": "daraxonrasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ParVation Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-09-01",
      "completion_date": "2029-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-19T23:00:02.906Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07756281"
    },
    {
      "nct_id": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Unresectable Solid Tumor",
        "Clear Cell Renal Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Non-Small Cell Lung Cancer Squamous",
        "Non-Small Cell Lung Cancer Non-squamous",
        "Colorectal Cancer (MSI-H)",
        "Gastric Cancer",
        "Cervical Cancer",
        "Basal Cell Carcinoma",
        "Bladder Cancer",
        "Merkel Cell Carcinoma",
        "Squamous Cell Carcinoma of Head and Neck",
        "Cutaneous Squamous Cell Carcinoma",
        "Pleural Mesothelioma",
        "Esophageal Cancer",
        "Endometrial Carcinoma",
        "Solid Tumor",
        "Solid Tumor, Adult",
        "MSI-H Solid Malignant Tumor",
        "Cancer With A High Tumor Mutational Burden",
        "Epithelial Ovarian Carcinoma",
        "Primary Peritoneal Cancer",
        "Gastroesophageal Junction (GEJ) Cancer",
        "Acral Melanoma",
        "Mucosal Melanoma",
        "Cutaneous Melanoma",
        "DMMR Solid Malignant Tumor",
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "MSI-H Cancer",
        "DMMR Cancer",
        "Pancreas Adenocarcinoma (MSI-H)",
        "Skin Cancer",
        "Viral Cancer",
        "Cervical Cancers",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "MDNA11",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medicenna Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2021-08-27",
      "completion_date": "2028-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-19T23:00:02.906Z",
      "location_count": 7,
      "location_summary": "San Diego, California • San Francisco, California • Santa Monica, California + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05086692"
    },
    {
      "nct_id": "NCT00968175",
      "title": "Endoscopic Ultrasound (EUS) Guided-Celiac Plexus Neurolysis (CPN) in Unresectable Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Ultrasound guided celiac plexus neurolysis (CPN)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2009-06",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-06-04",
      "last_synced_at": "2026-11-19T23:00:02.906Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Orlando, Florida",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00968175"
    },
    {
      "nct_id": "NCT03076216",
      "title": "A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Unresectable Locally Advanced Pancreatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "OncoSil™",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "OncoSil Medical Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2017-08-01",
      "completion_date": "2020-11-28",
      "has_results": false,
      "last_update_posted_date": "2021-07-13",
      "last_synced_at": "2026-11-19T23:00:02.906Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Tampa, Florida • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03076216"
    },
    {
      "nct_id": "NCT06984562",
      "title": "Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)"
      ],
      "interventions": [
        {
          "name": "Adaptive Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2025-08-20",
      "completion_date": "2029-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-19T23:00:02.906Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06984562"
    },
    {
      "nct_id": "NCT01318642",
      "title": "Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Pancreas",
        "Locally Advanced",
        "Unresectable"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "AMG 479",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NantBioScience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2012-05-31",
      "completion_date": "2012-12-03",
      "has_results": true,
      "last_update_posted_date": "2024-11-08",
      "last_synced_at": "2026-11-19T23:00:02.906Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Knoxville, Tennessee",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01318642"
    },
    {
      "nct_id": "NCT03736720",
      "title": "Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Digestive System Neuroendocrine Carcinoma",
        "Locally Advanced Pancreatic Neuroendocrine Carcinoma",
        "Metastatic Digestive System Neuroendocrine Carcinoma",
        "Metastatic Pancreatic Neuroendocrine Carcinoma",
        "Refractory Digestive System Neuroendocrine Carcinoma",
        "Refractory Pancreatic Neuroendocrine Carcinoma",
        "Unresectable Digestive System Neuroendocrine Carcinoma",
        "Unresectable Pancreatic Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Liposomal Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-06-17",
      "completion_date": "2024-08-26",
      "has_results": true,
      "last_update_posted_date": "2025-01-30",
      "last_synced_at": "2026-11-19T23:00:02.906Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Stony Brook, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03736720"
    },
    {
      "nct_id": "NCT00547144",
      "title": "Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Dendritic Cell Immunotherapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "George Albert Fisher",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2005-10",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2012-11-08",
      "last_synced_at": "2026-11-19T23:00:02.906Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00547144"
    },
    {
      "nct_id": "NCT03977233",
      "title": "Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma (PDAC)",
        "Cancer of Pancreas",
        "Pancreatic Cancer, Adult",
        "Pancreas Adenocarcinoma",
        "Pancreatic Neoplasms",
        "Pancreatic Cancer Non-resectable",
        "Pancreatic Cancer Resectable"
      ],
      "interventions": [
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 45,
      "start_date": "2019-06-12",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-11-19T23:00:02.906Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03977233"
    }
  ]
}